Contact
searchSearch
HMP Global

Hepatology Excellence Forum

Hepatology
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Expert Roundtable
GLP-1s, Resmetirom, Dual Therapy and More: Roundtable Continued
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on treatment for MASLD/MASH, the expert roundtable members delve into treatment of early-stage cirrhosis and the utility of bariatric surgery for a subset of patients with these liver diseases.
Continuing their discussion on...
03/30/2026
Gastroenterology
Expert Roundtable
Approved Medications for MASLD/MASH
03/30/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable discussion, Drs Afdhal, Bansal, and Younossi review the approved medications resmetirom and GLP-1 receptor agonists for MASLD/MASH, including how they work, selecting patients best suited for each, using dual...
In Part 5 of this roundtable...
03/30/2026
Gastroenterology
Treatment Guidance
Managing MASLD and MASH: Expert Roundtable Part 4
01/27/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
As hepatologists Nezam Afdhal, Meena Bansal, and Zobair Younossi continue their expert roundtable, the topic turns to the management of MASLD and MASH, including the best use of two new types of drugs--resmetirom and the GLP-1 agonists.
As hepatologists Nezam Afdhal, Meena Bansal, and Zobair Younossi continue their expert roundtable, the topic turns to the management of MASLD and MASH, including the best use of two new types of drugs--resmetirom and the GLP-1 agonists.
As hepatologists Nezam Afdhal,...
01/27/2026
Gastroenterology
Expert Insights
When to Refer Patients to Hepatology for MASLD/MASH
01/27/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
The expert panel on MASLD and MASH continues its discussion with guidance on when a patients with suspected steatotic liver disease should be referred to a hepatology specialist.
The expert panel on MASLD and MASH continues its discussion with guidance on when a patients with suspected steatotic liver disease should be referred to a hepatology specialist.
The expert panel on MASLD and...
01/27/2026
Gastroenterology
Expert Insights
Screening for MASLD and MASH: Expert Roundtable Part 2
01/19/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In Part 2 of this expert roundtable Drs Afdhal, Bansal, and Younossi discuss how to determine which patients need to be screened for MASLD/MASH, how to conduct screening, and which modalities are best.
In Part 2 of this expert roundtable Drs Afdhal, Bansal, and Younossi discuss how to determine which patients need to be screened for MASLD/MASH, how to conduct screening, and which modalities are best.
In Part 2 of this expert...
01/19/2026
Gastroenterology
Expert Insights
Expert Roundtable on MASLD/MASH: Part 1
01/15/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart series on MASLD and MASH, Drs Nezam Afdhal, Meena Bansal, and Zobair Younossi provide an overview of the growing prevalence of metabolic-associated steatotic liver disease (MASLD) and metabolic-associated...
In part 1 of this multipart...
01/15/2026
Gastroenterology
Sid Barritt
How I Treat
How I Treat MASLD/MASH: Dr Sidney Barritt on Pharmacotherapy
01/08/2026
A. Sidney Barritt, MD
Dr Barritt discusses how he approaches the treatment of MASLD and MASH, both with medical therapies and lifestyle adaptations.
Dr Barritt discusses how he approaches the treatment of MASLD and MASH, both with medical therapies and lifestyle adaptations.
Dr Barritt discusses how he...
01/08/2026
Gastroenterology
Alan Bonder
Conference Coverage
Alan Bonder, MD, on New Therapies for Pruritis in Liver Disease
08/26/2025
Alan Bonder, MD
Dr Bonder recaps news from the European Association for the Study of the Liver meeting on new therapies being investigated for the relief of pruritis in patients with primary biliary cholangitis.
Dr Bonder recaps news from the European Association for the Study of the Liver meeting on new therapies being investigated for the relief of pruritis in patients with primary biliary cholangitis.
Dr Bonder recaps news from the...
08/26/2025
Gastroenterology
How I Treat MASLD/MASH: A Sidney Barritt, MD
Sid Barritt
Videos
How I Treat MASLD/MASH: A Sidney Barritt, MD
07/23/2025
Dr Barritt explains how he works with patients (MASH) to to encourage and implement lifestyle interventions that can ameliorate metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis.
Dr Barritt explains how he works with patients (MASH) to to encourage and implement lifestyle interventions that can ameliorate metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis.
Dr Barritt explains how he works...
07/23/2025
Gastroenterology

News

News
Lifetime Alcohol Intake Linked to Colorectal Cancer Risk
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology
Conference Coverage
E-Cigarette Use and Risk of Peptic Ulcer Disease: Findings from a National Cohort
10/27/2025
Rebecca Mashaw
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at the ACG meeting, investigators concluded that e-cigarette use—both current and former—is independently associated with a risk of peptic ulcer disease.
In an oral abstract presented at...
10/27/2025
Gastroenterology
Research Highlights
Liquid Biopsy Shows Potential in Cholangiocarcinoma Care
10/09/2025
Rebecca Mashaw
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights liquid biopsy’s emerging role in diagnosis and management of biliary tract cancers.
A recent review highlights...
10/09/2025
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use